Get the Stockscreener App
5.08
7.17%
0.34
After Hours:
5.08
Orchestra Biomed Holdings Inc stock is traded at $5.08, with a volume of 478.14K.
It is up +7.17% in the last 24 hours and up +18.97% over the past month.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
See More
Previous Close:
$4.74
Open:
$4.71
24h Volume:
478.14K
Relative Volume:
1.39
Market Cap:
$305.33M
Revenue:
$32.72M
Net Income/Loss:
$-54.64M
P/E Ratio:
-4.5047
EPS:
-1.1277
Net Cash Flow:
$-55.08M
1W Performance:
-2.03%
1M Performance:
+18.97%
6M Performance:
+11.40%
1Y Performance:
+85.40%
1-Day Range:
$4.71
$5.14
1-Week Range:
$4.71
$5.3492
52-Week Range:
$2.20
$5.78
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
5.08 | 326.37M | 32.72M | -54.64M | -55.08M | -1.1277 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Orchestra BioMed (OBIO) president sells 15,000 shares under trading plan - Stock Titan
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Insider plans to sell 15,000 Orchestra BioMed (OBIO) shares - Stock Titan
Orchestra BioMed (OBIO) CFO logs 3,076-share tax withholding - Stock Titan
Orchestra BioMed (NASDAQ: OBIO) exec cites tax share withholding and son's 2,000-share buy - Stock Titan
Orchestra BioMed (OBIO) officer sees shares withheld for RSU taxes - Stock Titan
Avoiding Lag: Real-Time Signals in (OBIO) Movement - Stock Traders Daily
Orchestra BioMed to Participate in the Wells Fargo 21st Annual Healthcare Conference - GlobeNewswire
Orchestra BioMed CEO to meet investors across two days in September - Stock Titan
Insiders Buying Orchestra BioMed Holdings Might Wish They Invested More, Stock Gains 29% - Moomoo
Orchestra (OBIO) Q2 2026 Results: Profit Per Share Clears Its Benchmark for the Current Session; Investor Response: Shares Finish 19.92% Higher in Latest TradingInvestor Earnings Call - vinanet.vn
Orchestra (OBIO) Reported Results Review: EPS Prints Above Forecast for the Current Session; Price Action: Shares Close 19.92% Higher at the CloseProfit Recovery Report - vinanet.vn
Orchestra BioMed Loss Widens as Pivotal Trials Advance - MyChesCo
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Orchestra BioMed (OBIO) director withholds 3,761 shares to cover RSU tax bill - Stock Titan
Orchestra BioMed (OBIO) director uses 5,145 shares to cover RSU tax withholding - Stock Titan
Orchestra BioMed (OBIO) director has 4,885 shares withheld for RSU tax - Stock Titan
Orchestra BioMed (OBIO) director reports 4,238 RSU tax-withholding shares - Stock Titan
Orchestra BioMed (OBIO) Holds Gains at $4.45, Consolidating Between Key Technical LevelsComposite Profile - vinanet.vn
Research Analysts Offer Predictions for OBIO Q3 Earnings - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - theglobeandmail.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Piper Sandler Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Orchestra BioMed Holdings, Inc. Stock 12‑Month Price Target Raised to $12.33, Implies 177% Upside - TradingView
Orchestra Biomed Holdings earnings beat by $0.01, revenue fell short of estimates - Investing.com Canada
Orchestra Biomed Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates - Investing News Network
OBIO Looks 87.4% Undervalued on GF Value™ Despite Challenging Fu - GuruFocus
Orchestra BioMed reports $24.1M Q2 loss, secures $35M capital - scanx.trade
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Orchestra BioMed (NASDAQ:OBIO) Announces Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Orchestra BioMed Reports Q2 2026 Results and Updates Progress on BACKBEAT and Virtue Pivotal Trials - Moomoo
Orchestra BioMed (NASDAQ: OBIO) widens H1 2026 loss amid heavy R&D spend - Stock Titan
Orchestra Biomed Holdings Inc (OBIO) Stock News Today - TradingKey
Orchestra Biomed Holdings Inc (OBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Orchestra BioMed (OBIO) Insider Darren Sherman Sells 15,000 Shar - GuruFocus
Darren Sherman Sells 15,000 Shares of Orchestra BioMed (NASDAQ:OBIO) Stock - marketbeat.com
Orchestra BioMed (OBIO) insider sale under 10b5-1 plan on August 3, 2026 - Stock Titan
Orchestra BioMed (OBIO) Projected to Announce Quarterly Earnings on Tuesday - marketbeat.com
Orchestra BioMed (NASDAQ: OBIO) insider details Rule 144 sales of 45,000 shares - Stock Titan
Orchestra BioMed (OBIO) Holds Near $4.00 as Shares Test Support ZoneAnalyst Upgrade Stocks - vinanet.vn
Orchestra Biomed Holdings Inc expected to post a loss of 39 cents a shareEarnings Preview - TradingView
OBIO|Orchestra Biomed Holdings Inc|Price:3.825|Chg%:+0.085 - TradingKey
Orchestra Biomed Holdings Inc (OBIO) Income Statement - TradingKey
Orchestra Biomed Holdings Inc (OBIO) Balance Sheet - TradingKey
Orchestra Biomed Holdings Inc (OBIO) Institutional Confidence - TradingKey
Orchestra Biomed Holdings Inc (OBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Orchestra BioMed Holdings, Inc. Revenue Breakdown – NASDAQ:OBIO - TradingView
Orchestra Biomed Holdings Inc (OBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
OBIO|Orchestra Biomed Holdings Inc|Price:3.980|Chg%:-0.010 - TradingKey
OBIO Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-Revenue Biotech Advances PipelineHealthcare Earnings Report - po-news-eg.net
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Orchestra Biomed Holdings Inc Stock (OBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sherman Darren | See Remarks |
Aug 03 '26 |
Sale |
4.09 |
15,000 |
61,350 |
1,154,327 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):